X4 Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell XFOR and other ETFs, options, and stocks.

About XFOR

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. 

CEO
Adam R. Craig
CEOAdam R. Craig
Employees
45
Employees45
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2010
Founded2010
Employees
45
Employees45

XFOR Key Statistics

Market cap
408.40M
Market cap408.40M
Price-Earnings ratio
-0.96
Price-Earnings ratio-0.96
Dividend yield
Dividend yield
Average volume
370.48K
Average volume370.48K
High today
$4.62
High today$4.62
Low today
$4.20
Low today$4.20
Open price
$4.48
Open price$4.48
Volume
399.98K
Volume399.98K
52 Week high
$4.83
52 Week high$4.83
52 Week low
$1.35
52 Week low$1.35

Stock Snapshot

The current X4 Pharmaceuticals(XFOR) stock price is $4.34, with a market capitalization of 408.4M. The stock trades at a price-to-earnings (P/E) ratio of -0.96.

As of 2026-05-12, X4 Pharmaceuticals(XFOR) stock has fluctuated between $4.20 and $4.62. The current price stands at $4.34, placing the stock +3.3% above today's low and -6.1% off the high.

X4 Pharmaceuticals(XFOR) shares are trading with a volume of 399.98K, against a daily average of 370.48K.

In the last year, X4 Pharmaceuticals(XFOR) shares hit a 52-week high of $4.83 and a 52-week low of $1.35.

In the last year, X4 Pharmaceuticals(XFOR) shares hit a 52-week high of $4.83 and a 52-week low of $1.35.

XFOR News

TipRanks 2h
X4 Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 6d
X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)

Reports Q1 revenue $2.71M, consensus $3.2M. “Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixafor in chr...

People also own

Based on the portfolios of people who own XFOR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.